Objectives Cognitive behavioural therapy (CBT) is recommended as a first-line treatment for depression and anxiety disorders, but its utilisation under Japan’s national health insurance remains poorly ...
Japan’s health ministry has endorsed the first stem-cell therapy derived from induced pluripotent stem cells (iPSCs) for Parkinson’s disease, a decision that could reshape how the world treats one of ...
Cellares is advancing the global expansion of its state-of-the-art automated cell therapy manufacturing platform. The company announced May 29, in collaboration with Mitsui Fudosan, the establishment ...
The Japanese government, industry and academia are deliberating health care policies and initiatives to boost Japan’s role in the future of regenerative medicine, experts at Bio Japan 2024 said, as ...
Sanofi’s rilzabrutinib designated breakthrough therapy in the US and orphan drug in Japan for the treatment of warm autoimmune hemolytic anemia Rilzabrutinib is the first and only investigational BTKi ...
Cellares, in collaboration with Mitsui Fudosan, a Japanese real estate developer, established Japan’s first next-gen commercial production site for CAR-T cell therapies. The facility is under ...
A population-based study in Japan has revealed a gradual increase in the rates of therapy-related acute myeloid leukemia ...
– Kite Cell Therapy Business Unit at Gilead Sciences K.K. Will Manage the Sales and Promotion Activities in Japan After the Marketing Authorization Transfer – SANTA MONICA, Calif. & TOKYO--(BUSINESS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results